Search: WFRF:(BUCHFELDER M) >
Comparing progressi...
Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
-
- Olsson, Daniel S, 1983 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
Buchfelder, M (author)
-
Schlaffer, S (author)
-
show more...
-
- Bengtsson, Bengt-Åke, 1944 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
- Jakobsson, K-E (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
- Johannsson, Gudmundur, 1960 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
- Nilsson, Anna G, 1968 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
show less...
-
(creator_code:org_t)
- 2009
- 2009
- English.
-
In: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 161:5, s. 663-9
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: An important safety issue with GH replacement therapy (GHRT) in hypopituitary patients with a history of a pituitary adenoma is the risk for tumour recurrence or enlargement. Design Case-control study. SUBJECTS AND METHODS: We studied tumour progression rate in 121 patients with hypopituitarism on the basis of non-functioning pituitary adenomas (NFPA) receiving long-term GHRT. A group of 114 NFPA patients not receiving GHRT who were matched in terms of duration of follow-up, gender, age, age at diagnosis and radiotherapy status were used as a control population. The average duration of GHRT was 10+/-4 years (range 2-17). RESULTS: In patients with a known residual adenoma, 63% had no detectable enlargement of tumour during the study. In patients who had no visible residual tumour prior to GHRT, 90% did not suffer from recurrence. In total, the 10-year tumour progression-free survival rate in patients with NFPA receiving GHRT was 74%. In the control population not receiving GHRT, the 10-year progression-free survival rate was 70%. Radiotherapy as part of the initial tumour treatment reduced the rate of tumour progression in both GHRT and non-GHRT patients to a similar extent. CONCLUSIONS: The rate of tumour progression was similar in this large group of GHRT patients and the control population not receiving GHRT. Our results provide further support that long-term use of GH replacement in hypopituitarism may be considered safe in patients with residual pituitary adenomas.
Keyword
- Adenoma
- pathology
- therapy
- Adult
- Aged
- Aged
- 80 and over
- Case-Control Studies
- Disease Progression
- Female
- Hormone Replacement Therapy
- adverse effects
- methods
- Human Growth Hormone
- administration & dosage
- Humans
- Hypopituitarism
- drug therapy
- pathology
- Insulin-Like Growth Factor I
- metabolism
- Kaplan-Meiers Estimate
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Neoplasm Recurrence
- Local
- pathology
- Pituitary Neoplasms
- drug therapy
- pathology
- Prospective Studies
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database